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Abstract
Background: Some people who suffer an upper gastrointestinal bleed or perforation die. The
mortality rate was estimated at 12% in studies published before 1997, but a systematic survey of
more recent data is needed. Better treatment is likely to have reduced mortality. An estimate of
mortality is helpful in explaining to patients the risks of therapy, especially with NSAIDs.
Methods: A systematic review of studies published before 1997, and between 1997 and 2008. Any
study architecture was acceptable if it reported on cases who died from any cause of upper
gastrointestinal bleed or perforation. Analyses were conducted separately for all cases, and those
prescribed NSAID or aspirin.
Results: Information was available for 61,067 cases (81% published since 1997) of whom 5,001
died. The mortality rate in all cases fell significantly, from 11.6% (95% confidence interval, 11.0 to
12.2) in pre-1997 studies to 7.4% (7.2 to 7.6) in those published since 1997. In 5,526 patients taking
NSAID or aspirin, mortality increased, from 14.7% (13.6 to 15.8) before 1997 to 20.9% (18.8 to
22.9) since 1997.
Conclusion:  Upper gastrointestinal bleed or perforation still carries a finite risk of death.
Differences in study architecture, population characteristics, risk factors, definition of mortality,
and reporting of outcomes impose limitations on interpreting effect size. Data published since 1997
suggest that mortality in patients suffering from an upper gastrointestinal bleed or perforation has
fallen to 1 in 13 overall, but remains higher at about 1 in 5 in those exposed to NSAID or aspirin.
Background
Some patients who have a gastrointestinal bleed or perfo-
ration will die [1]. Risk of mortality is probably higher in
older people [2], in people with concomitant diseases, or
with large ulcers in the posterior duodenal bulb or on the
lesser curvature [3]. Use of NSAIDs (non-steroidal anti-
inflammatory drugs) or aspirin is likely to contribute to
gastrointestinal bleeding and death [4].
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In the largest published systematic review to date, with
data from 1966 to 1996, Tramèr and colleagues assessed
the mortality risk of more than two months NSAID expo-
sure as 12% in 11,000 cases of gastrointestinal bleed or
perforation, though there was a large variation of between
6% and 16% [1]. Knowing the mortality of an event may
be an important element in explaining risk to patients.
Mortality estimates for gastrointestinal bleeding and car-
diovascular events have been used in examining how the
various risks of NSAIDs and coxib (cyclooxygenase-2
selective inhibitor) use can be explained to patients [5,6].
Descriptions of the risk of dying from a gastrointestinal
bleed or perforation vary significantly. For instance, an
experimental study on how patients deal with risk used
the following description "A small proportion of people may
die from stomach bleeding" (compared to risk of dying from
a heart attack which was given as 1 in 10 to 1 in 5) [5],
while another described the risk as 10% [6]. These are
quite different presentations, which may be interpreted
very differently, by professionals and by patients [7].
We wanted to examine the published literature since
1997, the date of the last systematic review on mortality
from upper gastrointestinal bleeding or perforation [1].
We hypothesized that better treatment of patients with a
bleed or perforation might have reduced the mortality rate
to below 12%. Modification of standard care leading to
changes in the baseline risk has been described in patients
with myocardial infarction [8], stroke [9], and with high
cholesterol [10]. We also hypothesised that mortality with
NSAID use might not have fallen because guidelines con-
cerning use of gastroprotective strategies with NSAIDs in
patients with at least one gastrointestinal risk factor are
not followed in 3 out of 4 patients [11].
Methods
Guidelines for quality of reporting of meta-analyses were
followed where appropriate [12]. We took data from a
previous systematic review [1] of studies published up to
and including 1996. To identify more recent studies (pub-
lished between 1997 and October 2008), we conducted a
MEDLINE (PubMed) search for full publications; the date
of the last search was 6 November 2008. The search was
limited to 'humans' and the search strategy involved a
combination of the search terms "non-steroidal anti-
inflammatory", "aspirin", "upper gastrointestinal" (or
"upper gastro-intestinal" or "upper GI"), "ulcer", "bleed-
ing", "haemorrhage", "perforation", "death", and "mor-
tality". We also contacted experts in the field for further
studies. Only a small proportion of observational studies
are identified through electronic searching [13,14]. Refer-
ence lists of retrieved studies, reviews, and articles that
commented on formulary policy were also searched care-
fully for further reports. No formal quality assessments
were made.
We identified reports of any kind of clinical study pub-
lished in any language that contained information about
mortality with upper gastrointestinal bleeding or perfora-
tion. We sought data on the number of patients experienc-
ing upper gastrointestinal bleeds or perforations (cases),
and the number of these cases who died (deaths). We
sought data on the total number of cases and deaths, and
those in patients using NSAIDs. NSAIDs included aspirin
when it was used as an analgesic, but not low dose aspirin
used for prophylaxis of myocardial infarction or stroke.
Coxibs were included in the broader definition of
NSAIDs.
We calculated mortality rates as the number of deaths
divided by the number of cases with 95% confidence
intervals (CI). This was done for all patients independent
of NSAID exposure and for NSAID users separately; we
were unable to identify non-NSAID users separately from
all patients, and so all patient data are "contaminated" by
the inclusion of patients who were taking NSAID or aspi-
rin. Similarly, we calculated mortality rates for all times,
and for the time periods 'prior to 1997' and '1997–2008'
separately. Where papers reported separate datasets for
different diagnoses (gastric, duodenal, or peptic ulcer; [4]
for instance), we used these separate datasets in any anal-
ysis. Definitions of mortality were taken as reported in the
original reports. Differences between proportions were
assessed using both the t-test and Fisher's exact test, using
an interactive Internet statistical package http://
www.quantitativeskills.com/sisa/index.htm. Two sided
tests were used, with statistical significance set at p < 0.05.
Results
Searches, and references from the previous systematic
review [1], provided 65 studies with 244,329 patients in
total, of whom 61,067 experienced an upper gastrointes-
tinal bleed or perforation, and of whom 5,001 died (we
provide all the references not included in [1] in Additional
file 1). Data from after 1997 made up 81% of the cases
and 74% of the deaths.
There were six randomised trials (292 cases of bleed or
perforation, 5 deaths), six cohort studies (12,024 bleeds
or perforations, 1404 deaths), eight case-control studies
(4,487 bleeds or perforations, 258 deaths), 39 case series
(39,908 bleeds or perforations, 2674 deaths), three case
reports (226 bleeds or perforations, 9 deaths), one yellow
card report (3,443 bleeds or perforations, 576 deaths),
one audit (524 bleeds or perforations, 52 deaths), and
one cross sectional study (163 bleeds or perforations, 23
deaths). In total, 77 data sets from these studies contrib-BMC Gastroenterology 2009, 9:41 http://www.biomedcentral.com/1471-230X/9/41
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uted data on 61,067 patients who had suffered a gastroin-
testinal bleed or perforation.
Figure 1 shows the mortality rate (as 95% CI) according to
study type and number of deaths. There were substantial
differences in mortality rates between different study
architectures. The causal relationship between death and
gastrointestinal complication was rarely examined, nor
was it possible to distinguish between bleed and perfora-
tion as cause of death. Characteristics of patients who died
were again rarely reported separately from the population
as a whole.
Mortality was reported in different ways; as a simple
report of death, 30-day mortality, death in hospital or at
home, upper-gastrointestinal-related death, and others.
Studies rarely stratified mortality according to a specific
diagnosis, and it was not possible to perform analyses
based on diagnosis. There were also inconsistencies
regarding reporting of NSAID use. Few studies differenti-
ated between use and non-use of NSAID (or aspirin).
Where such a distinction was made, NSAID use was usu-
ally inferred using prescription analysis, with prescrip-
tions for NSAID or aspirin filled within a defined period
before the bleed or perforation, usually 30 days. Adher-
ence to and details of NSAID therapy (dose, drug, fre-
quency) were rarely specified. Because of these limitations
it was feasible only to compare definite NSAID use with
all patient data, whether NSAIDs or aspirin were used or
not.
Table 1 shows mortality rates in all cases and in the 5,526
cases (9% of all cases) using NSAID or aspirin. Overall
average mortality was 8.2% (95% CI 8.0 to 8.4%). In stud-
ies published before 1997 it was 11.6% (11.0 to 12.2%),
and in studies published from 1997 onwards, it had fallen
to 7.4% (7.2 to 7.6%). These later studies contained 81%
of total cases and 74% of deaths. The mean reduction in
mortality was by 4.2% (3.6 to 4.8%), a statistically signif-
icant reduction (p < 0.00001, t-test and Fisher's exact test).
There was considerable variation between individual
studies, particularly where the number of cases was
smaller (Figure 2).
For cases identified as taking an NSAID or aspirin, mortal-
ity in studies published before 1997 was 14.7% (13.6 to
15.8%), rising to 20.9% (18.8 to 22.9%) in studies pub-
lished from 1997 onwards. These later studies contained
27% of total NSAID cases and 34% of deaths. The mean
increase in mortality was by 6.2% (3.8 to 8.5%), a statisti-
cally significant increase (p < 0.00001, t-test and Fisher's
exact test).
Mortality for cases taking an NSAID was higher than for
all cases, both in older and newer data sets, but excess
mortality for NSAID and aspirin users was greater in more
recent studies. Before 1997 mortality for NSAID and aspi-
rin users was an average of 3.1% higher (1.9 to 4.3; p <
0.00001). Between 1997 and 2008 mortality for NSAID
users was an average of 13.5% higher (11.4 to 15.6; p <
0.00001).
Most of the data (95% of cases and deaths) was in the 39
datasets with at least 200 cases, and studies with fewer
than 100 cases contributed little (Table 1). Effects of study
size were inconsistent. For all cases experiencing a bleed
or perforation there was no consistent trend; small studies
contributed 2,862 bleeds or perforations and 246 deaths.
Mortality by study type Figure 1
Mortality by study type. Mean and 95% CI of percentage mortality. Numbers in parenthesis indicate the number of deaths.BMC Gastroenterology 2009, 9:41 http://www.biomedcentral.com/1471-230X/9/41
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For patients on NSAIDs in these small studies, there were
only 617 cases with a bleed or perforation and only 31
deaths. Here the estimated mortality rate of 5.0% was less
than a third that found in larger studies (Table 1).
Discussion
Interpretation of these results needs to be tempered by the
limitations of the data. These are substantial, and include
differences in study architecture, population characteris-
tics, risk factors, definitions of mortality, reporting of out-
comes according to diagnosis (perforation or ulcer bleed),
and descriptions of use of NSAIDs, aspirin, or other ulcer-
ogenic drugs. All of these are likely to impact on the mag-
nitude of any mortality estimate, and influence any
judgement on how mortality is influenced by temporal or
therapeutic variables. Fifty-nine of 65 included studies
were observational, where we lack any quality assessment
tools that reproducibly detect bias.
For example, Figure 1 shows dramatic differences in mor-
tality estimates between different study designs, though
small numbers of actual deaths and cases imparts real
uncertainty in some cases, perhaps beyond the conven-
tional calculation of confidence intervals. Which of these
designs most accurately captures the mortality rate is an
interesting point. It could be argued, for instance, that ran-
domised trials with low mortality rates reflect publication
bias, or perhaps the stringent application of guidelines in
inclusion criteria limits exposure of at-risk patients and
that, consequently, external validity or applicability of
these data may be limited. However that may be, all study
designs agree that mortality with upper gastrointestinal
bleeding or perforation is clinically significant.
We could see no clear reason for the different mortality
rates between different study designs in which there were
at least 200 deaths (case control, yellow cards, cohorts,
and case series). It could be argued that the reason for this
is that yellow card reporting selects more serious events,
and a subsequently higher mortality rate, but that would
still leave a two-fold difference of 6% to 12% mortality.
Case mix probably contributes a great deal, and while
meta-regression might help to quantify the extent, incon-
sistent reporting of patient characteristics puts limits on its
power to do that. An analysis based on individual patient
data would be more powerful, but it is unlikely that suffi-
cient consistent patient data could be obtained retrospec-
tively. These difficulties point to the need for a large
ongoing prospective study capturing key demographic
and diagnostic data and outcomes, an approach likely to
distinguish both temporal changes and the influence of
drugs, like NSAIDs, that influence gastrointestinal bleed-
ing.
Information from 61,067 cases and 5,001 deaths was
available, with more than four times as much information
on mortality in patients with upper gastrointestinal bleed-
ing or perforation published during the period between
1997 and 2008 than previously (Table 1). Results showed
a significant and important reduction in mortality over
time, by an average of 4%, meaning that 1 fewer person in
every 20 who had an upper gastrointestinal bleed or per-
Table 1: Mortality rates in cases of upper gastrointestinal bleed or perforation according to date of publication and size of study, for all 
cases and those taking NSAID
All Cases Cases using NSAIDs
Number of Number of
Analysis Cases Deaths Mortality (%; 95% CI) Cases Deaths Mortality (%; 95% CI)
Overall 61067 5001 8.2
(8.0 to 8.4)
5526 904 16.4
(15.4 to 17.3)
By date of publication
Before 1997 [1] 11361 1319 11.6
(11.0 to 12.2)
4046 595 14.7
(13.6 to 15.8)
Between 1997 and 2008 49706 3682 7.4
(7.2 to 7.6)
1480 309 20.9
(18.8 to 22.9)
By number of cases
≥ 2000 35058 2410 6.9
(6.6 to 7.1)
3443 576 16.7
15.5 to 18.0)
200–1999 23147 2345 10.1
(9.7 to 10.5)
1465 297 20.3
(18.2 to 22.3)
1–199 2862 246 8.6
(7.6 to 9.6)
618 31 5.0
(3.3 to 6.7)BMC Gastroenterology 2009, 9:41 http://www.biomedcentral.com/1471-230X/9/41
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foration now dies, compared with before 1997. This
major decrease in mortality probably reflects improved
standards of care, as has been described in other settings
[8-10,15]. Despite these improvements, still on average 1
in 13 cases of upper gastrointestinal bleeding or perfora-
tion dies.
It is important to stress that the figure is an average.
Known risk factors for increased mortality will be
increased age, comorbid conditions, and position of the
bleed or perforation [2,3]. We accepted all studies report-
ing mortality with upper gastrointestinal bleeding, and
typically these occurred in older adults in whom medi-
cines may also increase risk of a bleed or perforation, and
possibly of mortality.
At least 9% of the total cases (5,526) were prescribed an
NSAID or aspirin in the period before a bleed or perfora-
tion. Not unexpectedly, mortality in this subgroup of
patients was significantly higher than for all cases. NSAIDs
and aspirin are known to increase the risk of upper gas-
trointestinal bleeding or perforation [16]. Also, NSAIDs
and aspirin, when administered in analgesic doses, may
delay diagnosis of, for instance, a painful perforation.
Finally, NSAIDs and aspirin, through platelet inhibition,
are likely to further increase the bleeding in a patient with
a bleeding ulcer. It is less evident, though, why in patients
with a bleed or perforation who were exposed to NSAIDs
or aspirin, average mortality increased from about 15%
before 1997 to about 21% after 1997. If improvement in
standards of care has led to a decrease in overall mortality
over time, this would imply that this improvement was
not evident in cases taking NSAIDs or aspirin, which is
unlikely to be the case. Overall mortality is probably a
poor estimate of the non-NSAID using population
because it includes patients using NSAIDs, aspirin, and
sometimes both [17]. Therefore the true excess mortality
in patients taking NSAIDs may be higher than that esti-
mated.
A number of publications have pointed out that small
numbers of events have the potential to produce the
wrong answer because of the random play of chance [18-
20]. It was possible to examine the effects of size in this
analysis (Table 1). Two observations are helpful. Firstly,
limiting studies with rare events to at least a study size of
Mortality rates in cases of upper GI (gastrointestinal) bleed or perforation, for all patients and those taking NSAID Figure 2
Mortality rates in cases of upper GI (gastrointestinal) bleed or perforation, for all patients and those taking 
NSAID. Size of symbol is proportional to number of deaths in each study (inset scale). Vertical line shows overall average 
mortality rate.BMC Gastroenterology 2009, 9:41 http://www.biomedcentral.com/1471-230X/9/41
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200 cases, in this data set, would have meant that 95% of
the information was captured in half the studies, and
would not have altered the results. Secondly, relying on
analyses with small numbers can produce an aberrant
result, as was seen in the analysis of mortality in patients
with bleed or perforation taking NSAIDs or aspirin. In the
smaller studies with fewer than 200 cases each, and with
a total of 31 deaths only, the event rate was less than a
third that seen in larger studies with many more cases. For
all cases, even smaller studies amassed almost 250 deaths,
and the event rate was consistent with larger studies. This
reiterates previous observation and theory [18-20] that
with a small number of events in individual studies or in
systematic reviews or meta-analyses, incorrect results may
occur by the random play of chance.
Despite the limitations this study is important because of
the large number of patients and events, with most infor-
mation coming from more recently published studies.
Even an average mortality rate is helpful in explaining the
implications of therapy to individual patients, as well in
calculating the economic implications of prescribing pol-
icies.
The limitations of the studies included in this review high-
light how better investigational criteria might be applied
in future to better understand and more reliably quantify
the relationship between a gastrointestinal bleed or perfo-
ration and death. Only very large prospective studies that
detail diagnosis, medication, comorbid conditions, and
report the details separately for those with the event and
those who die are likely to be useful, as a nationwide
study from Spain exemplifies [4].
Conclusion
Upper gastrointestinal bleed or perforation still carries a
finite risk of death. Differences in study architecture, pop-
ulation characteristics, risk factors, definition of mortality,
and reporting of outcomes impose limitations on inter-
preting effect size. Data published since 1997 suggest that
overall mortality in any patient with a bleed or perfora-
tion has fallen over time but is still about 1 in 13. Not
unexpectedly, mortality is even higher in patients with a
bleed or perforation who are exposed to NSAID or aspirin.
New knowledge is that in these patients, mortality appears
to have increased over time to about 1 in 5 since 1997.
Reasons for this increase remain to be elucidated.
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